Allogeneic Stem Cell Transplantation With Adoptive Immunotherapy in Epstein-Barr Virus Positive Recurrent/Refractory Hodgkins Lymphoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

June 30, 2017

Study Completion Date

December 31, 2017

Conditions
Hodgkins Lymphoma
Interventions
BIOLOGICAL

allogeneic donor derived LMP specific cytotoxic T-lymphocyte

LMP CTLs will be give at 3 timepoints post allogeneic stem cell transplantation around days 60 to 100, then 30 days apart for the next 2 infusions.

Trial Locations (1)

10595

New York Medical College, Valhalla

All Listed Sponsors
collaborator

Children's National Research Institute

OTHER

collaborator

Baylor College of Medicine

OTHER

collaborator

M.D. Anderson Cancer Center

OTHER

collaborator

City of Hope Medical Center

OTHER

collaborator

Johns Hopkins University

OTHER

collaborator

Ohio State University

OTHER

collaborator

University of Utah

OTHER

collaborator

University of Michigan

OTHER

lead

New York Medical College

OTHER